Medical Advocates

Nevirapine
(Viramune)
 
Journal Citations

General Reports
Animal Studies

Formulations/Dosing           
Safety/Tolerability
Pharmacokinetics      

Drug/Drug Interactions
Resistance
Viral Dynamics
Diagnostics/Monitoring
Adverse Events
Efficacy
Adolescent/Adult Treatment


Therapeutic Strategies 
Special Populations 
Pharmacogenetics
Investigator Interviews

Drug Failure





 

NVP Main Page  Main New/Newsworthy 

Home Page

 

 

 

Last Update:  March 03, 2017
Perinatal Journal Data are in the Perinatal Data Page
Pediatric Journal Data are in the Pediatric Data Page

 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

General Reports
 

 

FULL-TEXT ARTICLE
Plasma nevirapine concentrations predict virological and adherence failure in Kenyan HIV-1 infected patients with extensive antiretroviral treatment exposure.
Kimulwo MJ, Okendo J, Aman RA, et a
PLoS One
. 2017 Feb 24;12(2):e0172960.
Paper

Inhibition of CYP2B6 by Medicinal Plant Extracts: Implication for Use of Efavirenz and Nevirapine-Based Highly Active Anti-Retroviral Therapy (HAART) in Resource-Limited Settings.
Thomford NE, Awortwe C, Dzobo K, et al 
Molecules
. 2016 Feb 16;21(2). pii: E211.
Abstract

Effects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients.
Mhandire D, Lacerda M, Castel S, Mhandire K, et al 
OMICS
. 2015 Sep;19(9):553-562.
Abstract

FULL-TEXT ARTICLE
Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patient
Baxi SM, Greenblatt RM, Bacchetti P, et al
PLoS One
. 2015 Jun 8;10(6):e0129100.
Paper

FULL-TEXT ARTICLE
Proteomic analysis of serum and urine of HIV-monoinfected and HIV/HCV-coinfected patients undergoing long term treatment with nevirapine.
Wongtrakul J, Thongtan T, Roytrakul S, et al
Dis Markers
. 2014;2014:315824.
Paper

Enhanced oral bioavailability of nevirapine within micellar nanocarriers compared with Viramune®
Moretton MA, Cohen L, Lepera L, et al
Colloids Surf B Biointerfaces
. 2014 Jun 28;122C:56-65
Abstract

HLA Class I restricted CD8+ and Class II restricted CD4+ T cells are implicated in the pathogenesis of nevirapine hypersensitivity.
Keane NM, Pavlos RK, McKinnon E, et al
AIDS
. 2014 Jun 6.
Abstract

FULL-TEXT ARTICLE
Structures of HIV-1 RT-RNA/DNA ternary complexes with dATP and nevirapine reveal conformational flexibility of RNA/DNA: insights into requirements for RNase H cleavage.
Das K, Martinez SE, Bandwar RP, Arnold E.
Nucleic Acids Res
. 2014 May 31
Paper

Synergistic activity of tenofovir and nevirapine combinations released from polycaprolactone matrices for potential enhanced prevention of HIV infection through the vaginal route.
Dang NT, Sivakumaran H, Harrich D, et al
Eur J Pharm Biopharm. 2014 May 3
Abstract

FULL-TEXT ARTICLE
Exposure of Allium cepa Root Cells to Zidovudine or Nevirapine Induces Cytogenotoxic Changes.

Onwuamah CK, Ekama SO, Audu RA, et al
PLoS One. 2014 Mar 5;9(3):e90296
.
Paper

Chronic ethanol use in alcoholic beverages by HIV-infected patients affects the therapeutic window of stavudine, lamivudine and nevirapine during the 9-month follow-up period: using chronic alcohol-use biomarkers.
Bbosa GS, Kyegombe DB, Anokbonggo WW. et al
J Basic Clin Physiol Pharmacol
. 2014 Jan 27:1-12.
Abstract

Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy.
Scarsi KK, Fehintola FA, Ma Q,  et al
J Antimicrob Chemother
. 2014 Jan 19
Abstract

Lipid Metabolism and Cardiovascular Risk in HIV Infection: New Perspectives and the Role of Nevirapine.
Podzamczer D.
AIDS Rev.
2013 Nov 6;15(4).
Abstract

FULL-TEXT ARTICLE
Nevirapine-Based Regimens in HIV-Infected Antiretroviral-Naive Patients: Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Kawalec P, Kryst J, Mikrut A, Pilc A.
PLoS One
. 2013 Oct 7;8(10):e76587.
Paper

Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes?
Micheli JE, Chinn LW, Shugarts SB,  et al
Pharmacogenet Genomics. 2013 Aug 26.
Abstract

Detection of drug bioactivation in vivo: Mechanism of nevirapine-albumin conjugate formation in patients.
Meng X, Howarth A, Earnshaw CJ,
Chem Res Toxicol. 2013 Feb 28.
Abstract

In vitro Evaluation of the Therapeutic Potential of Nevirapine in Treatment of Human Thyroid Anaplastic Carcinoma.
Dong JJ, Zhou Y, Liu YT,  et al
Mol Cell Endocrinol
. 2013 Feb 22.
Abstract

Nevirapine Inhibits the Anti-HIV Activity of CD8+ Cells.
Liu L, Wang L, Huang L,  et al
J Acquir Immune Defic Syndr
. 2013 Feb
Abstract

Synthesis and biological evaluation of phosphonate analogues of nevirapine.
Parrish J, Tong L, Wang M, et al
Bioorg Med Chem Lett
. 2012 Dec 21.
Abstract


Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians.
Bertrand J, Chou M, Richardson DM, Verstuyft C, L
Pharmacogenet Genomics
. 2012 Oct 25
Abstract

Nevirapine use, prolonged antiretroviral therapy and high CD4 nadir values are strongly correlated with undetectable HIV-DNA and -RNA levels and CD4 cell gain.
Sarmati L, Parisi SG, Montano M, et al
J Antimicrob Chemother. 2012 Aug 21
Abstract

Evidence for nevirapine bioactivation in man: Searching for the first step in the mechanism of nevirapine toxicity.
Caixas U, Antunes AM, Marinho AT,  et al
Toxicology
. 2012 Jun 28.
Abstract

N348I in HIV-1 Reverse Transcriptase Counteracts the Synergy Between Zidovudine and Nevirapine.
Huey Yap S, Herman BD, Radzio J,  et al
J Acquir Immune Defic Syndr. 2012 Jun 27.
Abstract

Influence of CYP2B6 and ABCB1 SNPs on Nevirapine Plasma Concentrations in Burundese HIV-positive
Patients Using Dried Sample Spot Devices.
Calcagno A, D'Avolio A, Simiele M,  et al
Br J Clin Pharmacol
. 2011 Dec 22.
Abstract

Is nevirapine atropisomeric? Experimental and computational evidence for rapid conformational inversion.
Burke EW, Morris GA, Vincent MA, et al
Org Biomol Chem. 2011 Dec 12.
Abstract

Surface modified nevirapine nanosuspensions for viral reservoir targeting: In vitro and in vivo evaluation.
Shegokar R, Singh KK.
Int J Pharm
. 2011 Oct 1
Abstract

Targeting nevirapine delivery across human brain microvascular endothelial cells using transferrin-grafted poly(lactide-co-glycolide) nanoparticles.
Kuo YC, Lin PI, Wang CC.
Nanomedicine (Lond). 2011 Jun 27
Abstract

Nevirapine nanosuspensions for HIV reservoir targeting.
Shegokar R, Singh KK.
Pharmazie
. 2011 Jun;66(6):408-15.
Abstract

Targeting nevirapine delivery across human brain microvascular endothelial cells using transferrin-grafted poly(lactide-co-glycolide) nanoparticles.
Kuo YC, Lin PI, Wang CC.
Nanomedicine (Lond)
. 2011 Jun 27
Abstract

Effects of nevirapine and efavirenz on human adipocyte differentiation, gene expression,
and release of adipokines and cytokines.
Díaz-Delfín J, Del Mar Gutiérrez M, Gallego-Escuredo JM,  et al
Antiviral Res. 2011 May 17.
Abstract

FULL-TEXT PDF ARTICLE
Development of a liposomal nanodelivery system for nevirapine.
Ramana LN, Sethuraman S, Ranga U, Krishnan UM.
J Biomed Sci
. 2010 Jul 13;17(1):57
Paper

FULL-TEXT PDF ARTICLE
N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward
RNase H cleavage during plus-strand initiation.

Biondi MJ, Beilhartz GL, McCormick S, Gotte M.
J Biol Chem
. 2010 Jun 8
Paper

Modelling the binding of HIV-reverse transcriptase and nevirapine: an assessment of quantum mechanical and force field approaches and predictions of the effect of
mutations on binding.
Raju RK, Burton NA, Hillier IH
Phys Chem Chem Phys. 2010 May 17
Abstract

Study on the interaction between HIV reverse transcriptase and its non-nucleoside inhibitor nevirapine by capillary electrophoresis.
Chen W, Li W, Ling X, Wang X, Liu J.
J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Apr 24.
Abstract

Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir.
Moltó J, Deig E, Valle M,  et al 
Ther Drug Monit
. 2010 Feb;32(1):93-6.
Abstract

Simultaneous production and co-mixing of microparticles of nevirapine with excipients by supercritical antisolvent method for dissolution enhancement.
Sanganwar GP, Sathigari S, Babu RJ, Gupta RB.
Eur J Pharm Sci
. 2009 Dec 2.
Abstract

Assessment of Nevirapine Bioavailability From Targeted Sites in the Human Gastrointestinal Tract.
Macha S, Yong CL, Macgregor TR, et al 
J Clin Pharmacol
. 2009 Sep 30.
Abstract


Animal Studies
 

 
Naringin improves zidovudine- and stavudine-induced skeletal muscle complications in rats.
Adebiyi OO, Adebiyi OA, Owira P.  
Hum Exp Toxicol
. 2016 Mar 22. pii: 0960327116638726
Abstract

Sex differences in hepatic and intestinal contributions to nevirapine biotransformation in rats.
Pinheiro PF, Marinho AT, Antunes AM,  et al
Chem Biol Interact
. 2015
Mar 27
Abstract

Nevirapine induces testicular toxicity in Wistar rats: reversal effect of kolaviron (biflavonoid from Garcinia kola seeds).
Adaramoye OA, Akanni OO, Farombi EO.
J Basic Clin Physiol Pharmacol
. 2013 Jun 8:1-8.
Abstract

Studies on the toxicological effect of nevirapine, an antiretroviral drug, on the liver, kidney and testis of male Wistar rats.
Adaramoye OA, Adesanoye OA, Adewumi OM, Akanni O.

Hum Exp Toxicol
. 2011 Oct 25

Abstract

Bioavailability of nevirapine in rats after oral and subcutaneous administration, in vivo absorption from gastrointestinal segments and effect of bile on its absorption from duodenum.
Usach I, Peris JE.
Int J Pharm. 2011 Aug 6.
Abstract

Anti-HIV Drugs Nevirapine and Efavirenz Affect Anxiety-Related Behavior and Cognitive
Performance in Mice.
Romão PR, Lemos JC, Moreira J, et al
Neurotox Res
. .
Abstract

RAT CYP3A and CYP2B1/2 were not associated with nevirapine-induced
hepatotoxicity.
Walubo A, Barr S, Abraham AM.
Methods Find Exp Clin Pharmacol.
2006 Sep;28(7):423-31.

Abstract


Formulations/Dosing
 

 

Effect Of Combination Of Acrylic Polymers On The Release Of Nevirapine Formulated As Extended Release Matrix Pelletsusing Extrusion And Spheronization Technique.
Sharma A, Prasad A, Dua K, Singh G.
Curr Drug Deliv. 2014 Jun 5.
Abstract

FULL-TEXT ARTICLE
Preparation and characterisation of nevirapine oral nanosuspensions.
Raju A, Reddy AJ, Satheesh J, Jithan AV.
Indian J Pharm Sci. 2014 Jan;76(1):62-71
Paper

Finding of nevirapine extended release tablet remnants in stools does not threaten the success of combination antiretroviral therapy.
Stephan C, León W.
HIV Med. 2014 Feb;15(2):124-8.
Abstract

VERxVE 144 week results: nevirapine extended-release (NVP XR) QD versus NVP immediate-release (IR) BID with FTC/TDF in treatment-naïve HIV-1 patients.
Brinson C, Bogner J, Nelson M, et al
J Int AIDS Soc
. 2012 Nov 11;15(6):18236.
Abstract

FULL-TEXT ARTICLE
Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment.
Yone EW, Kengne AP.
HIV AID
S (Auckl)
. 2012;4:181-4.

Paper

Pharmacological and clinical evidence of nevirapine immediate- and extended-release formulations.
Ena J, Amador C, Benito C, Pasquau F.
HIV AIDS
(Auckl)
. 2012
Abstract

Once-Daily Nevirapine XR: A Brief Overview of the Safety and Efficacy of a New Formulation.
Bhatti L, Gladstein J.
J Int Assoc Physicians AIDS Care (
Chic)
. 2012 Aug 27
Abstract

Nevirapine extended-release for the treatment of HIV-1 infection.
Bogner JR.
Expert Rev Anti Infect Ther. 2012 Jan;10(1):21-30.
Abstract

Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION).
Arasteh K, Ward D, Plettenberg A, et al 
HIV Med.
2011 Dec 4.
Abstract

Guidelines for the use of extended-release nevirapine in HIV-infected patients.
Heil EL, Corbett AH.
Expert Opin Pharmacother. 2011 Oct 29
Abstract

Efficacy and Safety of Once-Daily Nevirapine- or Efavirenz-Based Antiretroviral Therapy in HIV-Associated Tuberculosis: A Randomized Clinical Trial.
Swaminathan S, Padmapriyadarsini C, Venkatesan P,  et al
Clin Infect Dis. 2011 Oct;53(7):716-24.
Abstract

Bioavailability of Extended-Release Nevirapine 400 and 300 mg in HIV-1: A Multicenter, Open-Label Study.
Battegay PM, Arasteh DK, Plettenberg DA, et al
Clin Ther
. 2011 Aug 26.
Abstract

Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients.
Gathe J, Andrade-Villanueva J, Santiago S, et al
Antivir Ther. 2011;16(5):759-69.
Abstract

FULL-TEXT ARTICLE
Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose lection in HIV-infected individuals.
Schipani A, Wyen C, Mahungu T, et al
J Antimicrob Chemother
. 2011 Mar 25
Paper

Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach.
Moltó J, Valle M, Miranda C ,et al
J Antimicrob Chemother. 2008 Jun 30.
Abstract

Once-daily dosing of nevirapine in HAART.
Clotet B.
J Antimicrob Chemother. 2007 Nov 14;
Abstract

Bioequivalence study of two nevirapine tablet formulations in human immunodeficiency virus-infected patients
Tarinas A, Tápanes RD, González D, et al

Farm Hosp. 2007 Jun;31(3):165-168.
Abstract


Safety/Tolerability
 

 
Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION).
Arasteh K, Ward D, Plettenberg A, et al 
HIV Med.
2011 Dec 4.
Abstract

Drug safety evaluation of maraviroc for the treatment of HIV infection.
Wasmuth JC, Rockstroh JK, Hardy WD.

Expert Opin Drug Saf
. 2011 Nov 26
Abstract
Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA).
Dart Trial Team 
Trop Med Int Health.
2008 Jan;13(1):6-16.

Abstract


Pharmacokinetics
           

 
Population pharmacokinetic model to analyze nevirapine multiple-peaks profile after a single oral dose.
Ibarra M, Vázquez M, Fagiolino P.
J Pharmacokinet Pharmacodyn. 2014 Jul 27.
Abstract

Population Pharmacokinetic and Pharmacogenetic Analysis of Nevirapine in Hypersensitive and Tolerant HIV-Infected Patients from Malawi.
Dickinson L, Chaponda M, Carr DF,  et al
Antimicrob Agents Chemother
. 2013 Nov 11.
Abstract

Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial.
Fillekes Q, Muro EP, Chunda C,  et al
J Antimicrob Chemother
. 2013 Jul 17.
Abstract

Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state.
Fan-Havard P, Liu Z, Chou M,  et al
Antimicrob Agents Chemother
. 2013 Mar 4
Abstract

Associations Between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 Alleles in Relation to Efavirenz and Nevirapine Pharmacokinetics in HIV-Infected Individuals.
Heil SG, van der Ende ME, Schenk PW, et al
Ther Drug Monit
. 2012 Feb 17.
Abstract

Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics.
Svensson E, van der Walt JS, Barnes KI, et al
Br J Clin Pharmacol. 2012 Feb 2.
Abstract

Nevirapine (NVP) pharmacokinetics (PK) and risk of rash and hepatitis among HIV-infected Sub-Saharan African Women.
Dong BJ, Zheng Y, Hughes MD, et al

AIDS
. 2012 Feb 1
Abstract

Population Pharmacokinetics of Nevirapine in HIV-1 infected Pregnant Women and their neonates (ANRS 12109).
Benaboud S, Ekouévi DK, Urien S, et al
Antimicrob Agents Chemother
. 2010 Oct 18
Abstract

Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients (ANRS12154).
Chou M, Bertrand J, Segeral O, Verstuyft C, et al
Antimicrob Agents Chemother
. 2010 Aug 9
Abstract

Pharmacokinetic Assessment of Nevirapine and Metabolites in HIV-1 Patients with Hepatic Fibrosis.
Cammett AM, Macgregor TR, Wruck JM, et al  
Antimicrob Agents Chemother. 2009 Jul 20.
Abstract

Nevirapine pharmacokinetics in HIV-infected and HIV/HCV-coinfected individuals.
Vogel M, Bertram N, Wasmuth JC, et al
J Antimicrob Chemother
. 2009 Mar 6.
Abstract
 

Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review.
Cooper C, van Heeswijk R.
HIV Med. 2007 Jan;8(1):1-7.

Abstract
 

A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy.
von Hentig N, Carlebach A, Gute P, et al
Br J Clin Pharmacol.
2006 Nov;62(5):552-9.
Abstract
 
Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals.
Almond LM, Edirisinghe D, Dalton M, et al 
Clin Pharmacol Ther. 2005 Aug;78(2):132-42
Abstract
 
Short communication: changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations.
De Requena DG, Jimenez-Nacher I, Soriano V.

AIDS Res Hum Retroviruses. 2005 Jun;21(6):555-9.
Abstract
 
Race Is Not Associated with Nevirapine Pharmacokinetics.
De Maat MM, Nellen JF, Huitema AD   
Ther Drug Monit.
2004 Aug;26(4):456-458.
Abstract
 
No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease
inhibitors.
Dailly E, Billaud E, Reliquet V 
Eur J Clin Pharmacol. 2004 May 20
Abstract

Exposure of normal and transformed cells to nevirapine, a reverse transcriptase inhibitor, reduces cell growth and promotes differentiation.
Mangiacasale R, Pittoggi C, Sciamanna I, et al.

Oncogene 2003 May 8;22(18):2750-61
Abstract

Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals.
De Maat MM, Huitema AD, Mulder JW, et al
.
Br J Clin Pharmacol 2002 Oct;54(4):378-85
Abstract

Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals.
De Maat MM, Huitema AD,Mulder JW, et al.
Br J Clin Pharmacol 2002 May;53(5):552P
Abstract

Pharmacokinetic profiles of nevirapine and indinavir in various fractions of seminal  plasma.
v
an Praag RM, Repping S, de Vries JW, et al.
Antimicrob Agents Chemother
2001Oct;45(10):2902-2907
Abstract

FULL-TEXT ARTICLE
Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
Zhou XJ, Sheiner LB, D'Aquila RT, et al  
Antimicrob Agents Chemother 1999
Paper

 

Viral Dynamics
 

 
Low Trough Plasma Concentrations of Nevirapine Associated with Virologic Rebounds in HIV-Infected Patients Who Switched from Protease Inhibitors (April).
Duong M, Buisson M, Peytavin G, et al  
Ann Pharmacother
. 2005 Feb 15;
Abstract
 
Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy.
Parienti JJ, Massari V, Descamps D, et al
Clin Infect Dis. 2004 May 1;38(9):1311-6.
Abstract
 
Virologic and Immunologic Response to Regimens Containing Nevirapine or Efavirenz  in Combination with 2 Nucleoside Analogues in the Italian Cohort Naive
Antiretrovirals (I.Co.N.A. St
udy)  
Cozzi-Lepri A, Phillips AN, Monforte Ad A, et al.
J Infect Dis 2002 Apr 15;185(8):1062-1069
Abstract
 
Mechanism of Virologic Failure After Substitution of a Protease Inhibitor by Nevirapine in Patients With Suppressed Plasma HIV-1 RNA.
Masquelier B, Neau D, Chene G, et al.
J Acquir Immune Defic Syndr 2001 Dec 1;28(4):309-12 

Abstract
 

Resistance
 

 
Compensatory Role of Double Mutation N348I/M184V on Nevirapine Binding Landscape: Insight from Molecular Dynamics Simulation.
Karubiu W, Bhakat S, Soliman ME.
Protein J
. 2014 Aug 9.
Abstract

Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial.
Fillekes Q, Muro EP, Chunda C,  et al
J Antimicrob Chemother
. 2013 Jul 17.
Abstract

FULL-TEXT ARTICLE
Identification of Drug Resistant Mutations in HIV-1 CRF07_BC Variants Selected by Nevirapine In Vitro.
Wu H, Zhang HJ, Zhang XM,  et al
PLoS One
. 2012;7(9):e44333.
Paper

FULL-TEXT ARTICLE
P
anel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine.
Balamane M, Varghese V, Melikian GL, et al
Antimicrob Agents Chemother. 2012 Aug;56(8):4522-4
Paper

FULL-TEXT ARTICLE
Impact of Novel Resistance Profiles in HIV-1 Reverse Transcriptase on Phenotypic Resistance to NVP,
Jiao L, Li H, Li L,  et al 
AIDS Research and Treatment Vol 2012 , Art ID 637263
Paper

ULL-TEXT ARTICLE|
Resistance Patterns Selected by Nevirapine vs. Efavirenz in HIV-Infected Patients Failing First-Line Antiretroviral Treatment:

A Bayesian Analysis

Ngo-Giang-Huong N,  Jourdain G, Amzal B, et al
PLoS ONE
6(11): e27427
Paper

A376S in the Connection Subdomain of HIV-1 Reverse Transcriptase Confers Increased Risk of Virological Failure to Nevirapine Therapy.
Paredes R, Puertas MC, Bannister W, et al
J Infect Dis
. 2011 Sep;204(5):741-752.
Abstract

Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis.
Fogel J, Hoover DR, Sun J, et al
AIDS
. 2011 Apr 24;25(7):911-917.
Abstract

Estimating Frequencies of Minority Nevirapine Resistant Strains in Chronically HIV-1 Infected Individuals Naive to Nevirapine in Using Stochastic Simulations and a
Mathematical Model
Gadhamsetty S, Dixit NM
J Virol. 2010 Jul 28.
Abstract

Ultrasensitive Detection of Minor Drug-Resistant Variants for HIV After Nevirapine Exposure Using Allele-Specific PCR: Clinical Significance.
Rowley CF, Boutwell CL, Lee EJ, et al
AIDS Res Hum Retroviruses
. 2010 Mar;26(3):293-300
Abstract

Combination of V106I and V179D Polymorphic Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confers Resistance to Efavirenz and Nevirapine but not to Etravirine.
Gatanaga H, Ode H, Hachiya A,  et al 
Antimicrob Agents Chemother
. 2010 Feb 1
Abstract


 

 

Diagnostics/Monitoring
 

 
FULL-TEXT ARTICLE
Proteomic Analysis of Serum and Urine of HIV-Monoinfected and HIV/HCV-Coinfected Patients Undergoing Long Term Treatment with Nevirapine.
Wongtrakul J, Thongtan T, Roytrakul S, et al 
Dis Markers
. 2014;2014:315824.
Paper

Comparative chromatography-mass spectrometry studies on the antiretroviral drug nevirapine-Analytical performance characteristics in human plasma determination.
Sichilongo K, Chinyama M, Massele A, Vento S.
J Chromatogr B Analyt Technol Biomed Life Sci
. 2014Jan 15;945-946:101-9
Abstract

Nevirapine Concentrations in Saliva Measured by Thin Layer Chromatography and Self-Reported Adherence in Patients on Antiretroviral Therapy at Kilimanjaro Christian Medical Centre, Tanzania.
George L, Muro EP, Ndaro A, et al
Ther Drug Monit
. 2013 Dec 3
Abstract

FULL-TEXT ARTICLE
Simple, precise and accurate HPLC method of analysis for nevirapine suspension from human plasma.
Halde S, Mungantiwar A, Chintamaneni M
Indian J Pharm Sci. 2011 Jul;73(4):416-21.
Paper

Use of dried blood spots for the determination of plasma concentrations of nevirapine and efavirenz.
Kromdijk W, Mulder JW, Rosing H, et al
J Antimicrob Chemother
. 2012 Feb 1
Abstract

Microanalysis of the antiretroviral nevirapine in human hair from HIV-infected patients by liquid chromatography-tandem mass spectrometry.
Huang Y, Yang Q, Yoon K, et al
Anal Bioanal Chem. 2011 Aug 17
Abstract

Evidence-based Therapeutic Drug Monitoring for Nevirapine
Muret P, Piedoux S, Solas C, Quaranta S.
Therapie. 2011 May-Jun;66(3):187-95
Abstract

FULL-TEXT ARTICLE
Measuring Enzymatic HIV-1 Susceptibility to Two Reverse Transcriptase Inhibitors as a Rapid and Simple Approach to HIV-1 Drug-Resistance Testing.
Hoffmann D, Garcia AD, Harrigan PR, et al
PLoS One
. 2011;6(7):e22019.

Paper


Usefulness of methadone plasma concentration measurement in patients receiving nevirapine or efavirenz.
Pelet A, Favrat B, Cavassini M,
Am J Drug Alcohol Abuse. 2011 Jul;37(4):264-8
Abstract

Usefulness of Methadone Plasma Concentration Measurement in Patients Receiving Nevirapine or Efavirenz.
Pelet A, Favrat B, Cavassini M, et al
Am J Drug Alcohol Abuse. 2011 Jun 23
Abstract

Determination of nevirapine in plasma by GC-MS.
Vogel M, Bertram N, Wasmuth JC, et al
J Chromatogr Sci. 2010 Feb;48(2):91-4.
Abstract

Quantifying the Metabolic Activation of Nevirapine in Patients by Integrated Applications
of NMR and Mass Spectrometries.
Srivastava A, Lian LY, Maggs JL, et al 
Drug Metab Dispos. 2009 Oct 1.
Abstract

 

 

Efficacy
       

General Reports
 
 
Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
Mbuagbaw L, Mursleen S, Irlam JH, et al
Cochrane Database Syst Rev
. 2016 Dec 10;12:CD004246
Paper

Finding of nevirapine extended release tablet remnants in stools does not threaten the success of combination antiretroviral therapy
Stephan C, León W.
HIV Med. 2013 Sep 23.

Abstract

Long-term clinical and immunologic outcomes of HIV-infected women with and without previous exposure to nevirapine.
Mudiope PK, Kim S, Wabwire D, et al
Trop Med Int Health
. 2013 Jan 4.
Abstract

Long-term durability of nevirapine-based ART in a cohort of 82 patients after induction with protease inhibitor treatment.
Rump J, Hoehl J, Rosenberg C.
J Int AIDS Soc. 2012 Nov 11;15(6):18247.
Abstract

Contemporary Role of Nevirapine in HIV Treatment.
Coster LO, Kumar PN.
AIDS Re
v
. 2012 Apr;14(2):132-44.
Abstract

FULL-TEXT PDF ARTICLE
Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected
patients with or without viral hepatitis B or C infection in Cameroon.

Tchatchueng Mbougua JB, Laurent C, et al
 
BMC Public Health. 2010 Mar 1;10(1):105
Paper

Suboptimal Etravirine Activity is Common During Failure of Nevirapine-based Combination Antiretroviral Therapy in a Cohort Infected with non-B subtype HIV-1.
Taiwo B, Chaplin B, Penugonda S, et al  
Curr HIV Res. 2010 Feb 18.
Abstract


Safety and efficacy of once-daily nevirapine dosing: a multicohort study.
Calmy A, Vallier N, Nguyen A, Lange JM,  et al
Antivir Ther
. 2009;14(7):931-938.
Abstract

Long-Term Effectiveness and Safety Outcomes in HIV-1-Infected Patients After a Median Time of 6 Years on Nevirapine.
Rodríguez-Arrondo F, Aguirrebengoa K, et al
Curr HIV Res
. 2009 Sep;7(5):526-532
Abstract

Long-term follow-up of nevirapine-treated patients in a single-centre cohort.
Colafigli M, Di Giambenedetto S, Bracciale L, et al 
HIV Med. 2009 May 6.
Abstract

Plasma Nevirapine Levels and 24-Week Efficacy in HIV-Infected Patients Receiving Nevirapine-Based Highly Active Antiretroviral Therapy with or without Rifampicin.
Manosuthi W, Sungkanuparph S, Thakkinstian A, et al
Clin Infect Dis.
2006 Jul 15;43(2):253-5
Abstract
 

Long-Term Safety and Efficacy of Nevirapine-Based Approaches in HIV Type 1-Infected Patients.
Bonjoch A, Paredes R, Domingo P, et al  
AIDS Res Hum Retroviruses
. 2006 Apr;22(4):321-9.
Abstract

The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART.
van Leth F, Andrews S, Grinsztejn B, Wilkins E
AIDS. 2005 Mar 25;19(5):463-471
Abstract
 

NVP/RTV
 
  Nevirapine-raltegravir combination, a NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients.
Reliquet V, Chirouze C, Allavena C,  et al
Antivir Ther
. 2013 Oct 22
Abstract

NVP vs ATV
 
  A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined withtenofovir/emtricitabine in treatment-naïve patients.
Dejesus E, Mills A, Bhatti L, Conner C, Storfer S.
Int J Clin Pract. 2011 Dec;65(12):1240-9.
Abstract


Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial.
Soriano V, Arastéh K, Migrone H,  et al
Antivir Ther
. 2011;16(3):339-48.
Abstract

NVP vs EFV
 

 
A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine
clinical practice in Europe: a EuroSIDA study.
Reekie J, Reiss P, Ledergerber B, Sedlacek D, et al
HIV Med
. 2010 Aug 31
Abstract

Comparison of efavirenz and nevirapine in HIV-infected patients (NEEF Cohort).
Harmann M, Witte S, Brust J, et al
Int J STD AIDS.
2005 Jun;16(6):404-9.
Abstract
 

Plasma HIV-1 RNA Decline Within the First Two Weeks of Treatment Is Comparable for Nevirapine, Efavirenz, or Both Drugs Combined and Is Not Predictive of Long-Term Virologic Efficacy: A 2NN Substudy.
van Leth F, Huisamen CB, Badaro R, et al 
J
Acquir Immune Defic Syndr. 2005 Mar 1;38(3):296-300.
Abstract
 
Efavirenz Versus Nevirapine in Current Clinical Practice: A Prospective, Open-Label Observational Study.
Manfredi R, Calza L, Chiodo F. 
J Acquir Immune Defic Syndr. 2004 Mar 15;35(5):492-502.
Abstract

Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naive patients with advanced HIV infection.
Manosuthi W, Sungkanuparph S, Vibhagool A, et al
HIV Med.
2004 Mar;5(2):105-9.

Abstract
 

 
NVP vs LPV
 
  FULL-TEXT ARTICLE
Nevirapine- Versus Lopinavir/Ritonavir-Based Initial Therapy for HIV-1 Infection among Women in Africa: A Randomized Trial.
Lockman S, Hughes M, Sawe F, et al
PLoS Med
. 2012 Jun;9(6):e1001236.
Paper

A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study.
Reekie J, Reiss P, Ledergerber B, Sedlacek D, et al
HIV Med
. 2010 Aug 31

Abstract
 

NVP vs Tenofovir
 
  Immunological outcomes of Tenofovir versus Zidovudine-based regimens among people living with HIV/AIDS: a two years retrospective cohort study.
Ayele T, Jarso H, Mamo G.
AIDS Res Ther. 2017 Feb 1;14(1):5.
Abstract

NVP vs PIs
 

  The impact of nevirapine- versus protease inhibitor-based regimens on virological markers of HIV-1 persistence during seemingly suppressive ART.
Kiselinova M, Anna M, Malatinkova E,  et al
J Int AIDS Soc. 2014 Nov 2;17(4(Suppl 3)):19823.
Abstract

Generic
 

  Weight and body shape changes in a treatment-naive population after 6 months of nevirapine-based generic highly active antiretroviral therapy in South India.
Saghayam S, Kumarasamy N, Cecelia AJ, et al
Clin Infect Dis. 2007 Jan 15;44(2):295-300.
Abstract

Special Populations
 

Hemophiliacs
 
  Efavirenz and nevirapine plasma levels in HIV-infected patients with hemophilia.
Martorell M, Lopez RM, Ribera E
Enferm Infecc Microbiol Clin. 2005 Jun;23(6):349-5

Abstract
 
Methadone Users
 
  Usefulness of Methadone Plasma Concentration Measurement in Patients Receiving Nevirapine or Efavirenz.
Pelet A, Favrat B, Cavassini M, et al
Am J Drug Alcohol Abuse. 2011 Jun 23

Abstract

Pharmacogenetics
       

  FULL TEXT ARTICLE (Download instructions on webpage)
A Pharmacogenetics Study in Mozambican Patients Treated with Nevirapine: Full Resequencing of TRAF3IP2 Gene Shows a Novel Association with SJS/TEN Susceptibility.
Ciccacci C, Rufini S, Mancinelli S,  et al

Int J Mol Sci. 2015 Mar 12;16(3):5830-8.
Paper

Investigator Interviews
       

  José M. Gatell, MD, PhD
September 25, 2003

Drug Failure
       

  Low-Frequency Nevirapine (NVP)-Resistant HIV-1 Variants Are Not Associated With Failure of Antiretroviral Therapy in Women Without Prior Exposure to Single-Dose NVP.
Boltz VF, Bao Y, Lockman S,   et al
J Infect
Dis
. 2014 Jan 16
Abstract

FULL-TEXT PDF ARTICLE
Plasma Concentrations of Efavirenz and Nevirapine among HIV-Infected Patients with Immunological Failure Attending a Tertiary Hospital in North-Western Tanzania.
Gunda DW, Kasang C, Kidenya BR,  et al
PLoS One
. 2013 Sep 10;8(9):e75118
Paper

 

 


NVP Main Page  Main New/Newsworthy 

Home Page

 

 

 

Nevirapine Journal Data